315 related articles for article (PubMed ID: 22895931)
1. Comparison of speech and language therapy techniques for speech problems in Parkinson's disease.
Herd CP; Tomlinson CL; Deane KH; Brady MC; Smith CH; Sackley CM; Clarke CE
Cochrane Database Syst Rev; 2012 Aug; 2012(8):CD002814. PubMed ID: 22895931
[TBL] [Abstract][Full Text] [Related]
2. Speech and language therapy versus placebo or no intervention for speech problems in Parkinson's disease.
Herd CP; Tomlinson CL; Deane KH; Brady MC; Smith CH; Sackley CM; Clarke CE
Cochrane Database Syst Rev; 2012 Aug; 2012(8):CD002812. PubMed ID: 22895930
[TBL] [Abstract][Full Text] [Related]
3. A comparison of speech and language therapy techniques for dysarthria in Parkinson's disease.
Deane KH; Whurr R; Playford ED; Ben-Shlomo Y; Clarke CE
Cochrane Database Syst Rev; 2001; (2):CD002814. PubMed ID: 11406045
[TBL] [Abstract][Full Text] [Related]
4. A multicentre, randomised controlled trial to compare the clinical and cost-effectiveness of Lee Silverman Voice Treatment versus standard NHS Speech and Language Therapy versus control in Parkinson's disease: a study protocol for a randomised controlled trial.
Sackley CM; Rick C; Au P; Brady MC; Beaton G; Burton C; Caulfield M; Dickson S; Dowling F; Hughes M; Ives N; Jowett S; Masterson-Algar P; Nicoll A; Patel S; Smith CH; Woolley R; Clarke CE;
Trials; 2020 May; 21(1):436. PubMed ID: 32460885
[TBL] [Abstract][Full Text] [Related]
5. Speech and language therapy for dysarthria in Parkinson's disease.
Deane KH; Whurr R; Playford ED; Ben-Shlomo Y; Clarke CE
Cochrane Database Syst Rev; 2001; (2):CD002812. PubMed ID: 11406044
[TBL] [Abstract][Full Text] [Related]
6. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
[TBL] [Abstract][Full Text] [Related]
7. Lee Silverman Voice Treatment for dysarthria in patients with Parkinson's disease: a systematic review and meta-analysis.
Yuan F; Guo X; Wei X; Xie F; Zheng J; Huang Y; Huang Z; Chang Z; Li H; Guo Y; Chen J; Guo J; Tang B; Deng B; Wang Q
Eur J Neurol; 2020 Oct; 27(10):1957-1970. PubMed ID: 32539227
[TBL] [Abstract][Full Text] [Related]
8. Speech treatment in Parkinson's disease: Randomized controlled trial (RCT).
Ramig L; Halpern A; Spielman J; Fox C; Freeman K
Mov Disord; 2018 Nov; 33(11):1777-1791. PubMed ID: 30264896
[TBL] [Abstract][Full Text] [Related]
9. Speech therapy for children with dysarthria acquired before three years of age.
Pennington L; Parker NK; Kelly H; Miller N
Cochrane Database Syst Rev; 2016 Jul; 7(7):CD006937. PubMed ID: 27428115
[TBL] [Abstract][Full Text] [Related]
10. Speech and language therapy treatment on hypokinetic dysarthria in Parkinson disease: Systematic review and meta-analysis.
Muñoz-Vigueras N; Prados-Román E; Valenza MC; Granados-Santiago M; Cabrera-Martos I; Rodríguez-Torres J; Torres-Sánchez I
Clin Rehabil; 2021 May; 35(5):639-655. PubMed ID: 33233932
[TBL] [Abstract][Full Text] [Related]
11. Speech and language therapy for management of chronic cough.
Slinger C; Mehdi SB; Milan SJ; Dodd S; Matthews J; Vyas A; Marsden PA
Cochrane Database Syst Rev; 2019 Jul; 7(7):CD013067. PubMed ID: 31335963
[TBL] [Abstract][Full Text] [Related]
12. [The progress in the rehabilitation of dysarthria in Parkinson disease using LSVT (Lee Silverman Voice Treatment)].
Kamińska I; Zebryk-Stopa A; Pruszewicz A; Dziubalska-Kołaczyk K; Połczyńska-Fiszer M; Pietrala D; Przedpelska-Ober E
Otolaryngol Pol; 2007; 61(5):713-8. PubMed ID: 18552005
[TBL] [Abstract][Full Text] [Related]
13. Non-speech oral motor treatment for children with developmental speech sound disorders.
Lee AS; Gibbon FE
Cochrane Database Syst Rev; 2015 Mar; 2015(3):CD009383. PubMed ID: 25805060
[TBL] [Abstract][Full Text] [Related]
14. Single Word Intelligibility of Individuals with Parkinson's Disease in Noise: Pre-Specified Secondary Outcome Variables from a Randomized Control Trial (RCT) Comparing Two Intensive Speech Treatments (LSVT LOUD vs. LSVT ARTIC).
Schulz G; Halpern A; Spielman J; Ramig L; Panzer I; Sharpley A; Freeman K
Brain Sci; 2021 Jun; 11(7):. PubMed ID: 34199093
[TBL] [Abstract][Full Text] [Related]
15. Interventions for dysarthria due to stroke and other adult-acquired, non-progressive brain injury.
Mitchell C; Bowen A; Tyson S; Butterfint Z; Conroy P
Cochrane Database Syst Rev; 2017 Jan; 1(1):CD002088. PubMed ID: 28121021
[TBL] [Abstract][Full Text] [Related]
16. Neural Correlates of Hypokinetic Dysarthria and Mechanisms of Effective Voice Treatment in Parkinson Disease.
Baumann A; Nebel A; Granert O; Giehl K; Wolff S; Schmidt W; Baasch C; Schmidt G; Witt K; Deuschl G; Hartwigsen G; Zeuner KE; van Eimeren T
Neurorehabil Neural Repair; 2018 Dec; 32(12):1055-1066. PubMed ID: 30444176
[TBL] [Abstract][Full Text] [Related]
17. Lee Silverman Voice Treatment versus standard speech and language therapy versus control in Parkinson's disease: a pilot randomised controlled trial (PD COMM pilot).
Sackley CM; Smith CH; Rick CE; Brady MC; Ives N; Patel S; Woolley R; Dowling F; Patel R; Roberts H; Jowett S; Wheatley K; Kelly D; Sands G; Clarke CE;
Pilot Feasibility Stud; 2018; 4():30. PubMed ID: 29344405
[TBL] [Abstract][Full Text] [Related]
18. Lee Silverman Voice Treatment versus standard speech and language therapy versus control in Parkinson's disease: preliminary cost-consequence analysis of the PD COMM pilot randomised controlled trial.
Scobie S; Jowett S; Lambe T; Patel S; Woolley R; Ives N; Rick C; Smith C; Brady MC; Clarke C; Sackley C
Pilot Feasibility Stud; 2021 Aug; 7(1):154. PubMed ID: 34372913
[TBL] [Abstract][Full Text] [Related]
19. PD Check-In: The development and trial of a supported self-management program for people with Parkinson's disease following intensive speech intervention.
Finnimore A; Theodoros D; Rumbach AF
Int J Lang Commun Disord; 2022 Jan; 57(1):138-151. PubMed ID: 34767290
[TBL] [Abstract][Full Text] [Related]
20. Effects of intensive voice treatment (the Lee Silverman Voice Treatment [LSVT]) on vowel articulation in dysarthric individuals with idiopathic Parkinson disease: acoustic and perceptual findings.
Sapir S; Spielman JL; Ramig LO; Story BH; Fox C
J Speech Lang Hear Res; 2007 Aug; 50(4):899-912. PubMed ID: 17675595
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
